This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Assembly Biosciences (ASMB) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 733.33% and 28.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences (ASMB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Assembly Biosciences (ASMB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Assembly Biosciences (ASMB) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns
Why Assembly Biosciences (ASMB) Stock Might be a Great Pick
by Zacks Equity Research
Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Assembly Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Assembly Biosciences
Assembly Biosciences (ASMB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.98% and 27.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?
by Zacks Equity Research
Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.
Top Ranked Momentum Stocks to Buy for October 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 18th
Will Assembly Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Assembly Biosciences.
Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 34.55% and -20.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
by Zacks Equity Research
Continued price erosion and intensifying competition in generic drug market is negatively impacting the top line of industry participants. However, stabilizing outlook is encouraging.
Mylan (MYL) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Mylan (MYL) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Amphastar Pharmaceuticals (AMPH) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.71% and 33.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Assembly Biosciences (ASMB) Stock
by Zacks Equity Research
Assembly Biosciences (ASMB) needs investors to pay close attention to the stock based on moves in the options market lately.
Assembly Biosciences (ASMB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -44.44% and -2.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences
by Zacks Equity Research
Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences
New Analyst Coverage Puts the Spotlight on These 5 Stocks
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
New Strong Sell Stocks for September 18th
by Zacks Equity Research
Here are 4 stocks added to the Zacks Rank #5 (Strong Sell) List today: